Recombinant Human Anti-HIV-1 Antibody (VRC26.25) (CAT#: PABL-140)

Recombinant Human Antibody (VRC26.25) is capable of binding to HIV-1, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody neutralized 57% of diverse clade 43 viral isolates and 70% of clade C isolates with remarkable potency.

  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Neutralization profiles of PGDM1400 and CAP256-VRC26.25 against a multi-clade panels of 208 pseudoviruses (A) and highlighting specifically the activity of both bNAbs against clade C pseudoviruses (B).

(A) Each bar represents the IC80 (μg/ml) of PGDM1400 (upper graph) or CAP256-VRC26.25 (lower graph) against a single virus. Viruses are ranked according to increasing IC80 values. Bars reaching the dotted line represent IC80 values>50 μg/mL. The red bars highlight the IC80 values for PGDM1400 (upper graph) or CAP256-VRC26.25 (lower graph) against SHIV-325c. (B) IC80 values for PGDM1400 and CAP256-VRC26.25 against SHIV-325c (red dot) and against the clade C pseudoviruses included in panel (A). The horizontal bars represent the mean of IC80 values of neutralizable pseudoviruses.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.

Figure 2 Neutralization of SHIV-325c by CAP256-VRC26.25, PGDM1400 and PG9

Neutralization was measured using replication competent challenge stock SHIV-325c infection of TZM-bl cells. All 3 antibodies showed 100% neutralization of SHIV-325c with no evidence of a plateau effect below 100% neutralization.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.

Figure 3 Protective efficacy of PGDM1400 and CAP256-VRC26.25-LS against SHIV-325c in rhesus macaques

Plasma viral RNA (log RNA copies/mL) are shown for animals that received placebo control (A), 2 mg/kg PGDM1400 (B), 0.4 mg/kg PGDM1400 (C), 0.08 mg/kg PGDM1400 (D), 2 mg/kg CAP256-VRC26.25-LS (E), 0.4 mg/kg CAP256-VRC26.25-LS (F), or 0.08 mg/kg CAP256-VRC26.25-LS (G). All placebo controls became infected. Protection was observed in all animals that received CAP256-VRC26.25-LS at all doses. 1/5 animals in the PGDM1400 2 mg/kg dose group and 3/4 animals in the 0.08 mg/kg PGDM1400 dose group were infected. The assay sensitivity limit was>50 RNA copies/mL.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.

Figure 4 Serum concentration of CAP256-VRC26.25-LS and PGDM1400 in antibody treated animals

bNAb concentrations were determined by ELISA. The results show average serum concentrations of 19.8 μg/ml, 3.3 μg/ml and 0.75 μg/mL on the day of challenge in the CAP256-VRC26.25-LS 2 mg/kg, 0.4 mg/kg and 0.08 mg/kg groups, respectively, and 6.9 μg/mL, 2.5 μg/mL and 0.22 μg/mL on the day of challenge in the PGDM1400 2 mg/kg, 0.4 mg/kg and 0.08 mg/kg groups, respectively.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG
  • Specificity
  • Tested positive against native HIV-1 HIV-1
  • Species Reactivity
  • HIV-1
  • Clone
  • VRC26.25
  • Applications
  • WB, ELISA, Neut, FuncS

Applications

  • Application Notes
  • Neutralization of diverse, replication-competent SHIV challenge stocks (including SHIV-325c) or Env-pseudoviruses was evaluated in vitro by using TZM-bl target cells and a luciferase reporter assay. Briefly, HIV-1 Env pseudoviruses were generated by transfection in 293T cells, and SHIV challenge stocks were produced by transfection of 293T cells with infectious molecular clone plasmids, followed by propagation in human or rhesus PBMC. The rhesus PBMC derived stock of SHIV-AD8 was kindly provided by Dr. Malcolm Martin and SHIV-1157ipd3N4 was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Ruth Ruprecht. SHIV stocks or HIV-1 pseudoviruses were incubated with the antibody for 30 min at 37°C before TZM-bl cells were added. The protease inhibitor indinavir was added to assays with SHIV stocks to a final concentration of 1 μM to limit infection of target cells to a single round of viral replication. Luciferase expression was quantified 48 h after infection upon cell lysis and the addition of luciferin substrate (Promega).

Target

  • Alternative Names
  • HIV-1; human immunodeficiency virus

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

See other products for "HIV-1"

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

  • Verification code
    Click image to refresh the verification code.
© 2007 - 2020 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart